Lymphoma & Plasma Cell Disorders
Conference Coverage
Phase 3 study confirms biosimilarity of PF-05280586 with rituximab
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
News
Shorter R-CHOP regimen noninferior in certain DLBCL patients
SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy...
News
Regimen provides survival benefit in PTCL
SAN DIEGO—A newly approved treatment regimen provides a survival benefit over standard therapy for patients with CD30-positive peripheral T-cell...
News
Update shows durable responses in rel/ref DLBCL
SAN DIEGO—An updated analysis of the JULIET trial showed that tisagenlecleucel produced a high rate of durable responses in adults with relapsed...
Conference Coverage
TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant
SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to...
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
Conference Coverage
JULIET: CAR T cells keep trucking against DLBCL
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.
News
New PCNSL guidelines emphasize importance of patient fitness
New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis,...